Pfizer Inc. $PFE Stock Holdings Lifted by Pzena Investment Management LLC

Pzena Investment Management LLC raised its position in shares of Pfizer Inc. (NYSE:PFE) by 0.9% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 6,615,598 shares of the biopharmaceutical company’s stock after purchasing an additional 56,484 shares during the quarter. Pzena Investment Management LLC’s holdings in Pfizer were worth $168,565,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of PFE. Brighton Jones LLC boosted its stake in shares of Pfizer by 1,282.4% during the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock valued at $17,677,000 after buying an additional 618,117 shares during the period. Revolve Wealth Partners LLC grew its position in Pfizer by 12.5% during the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock worth $498,000 after buying an additional 2,087 shares in the last quarter. United Bank grew its holdings in shares of Pfizer by 12.4% during the 2nd quarter. United Bank now owns 58,087 shares of the biopharmaceutical company’s stock worth $1,408,000 after purchasing an additional 6,415 shares in the last quarter. Avidian Wealth Enterprises LLC raised its stake in shares of Pfizer by 9.4% in the 2nd quarter. Avidian Wealth Enterprises LLC now owns 19,945 shares of the biopharmaceutical company’s stock valued at $483,000 after buying an additional 1,712 shares in the last quarter. Finally, Phoenix Financial Ltd. raised its holdings in shares of Pfizer by 67.3% in the 2nd quarter. Phoenix Financial Ltd. now owns 76,603 shares of the biopharmaceutical company’s stock worth $1,856,000 after buying an additional 30,805 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

PFE has been the topic of a number of recent analyst reports. Scotiabank assumed coverage on Pfizer in a research note on Thursday, November 13th. They issued a “sector outperform” rating and a $30.00 price objective on the stock. Daiwa Securities Group cut shares of Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 target price for the company. in a research report on Thursday, February 12th. Morgan Stanley reduced their price objective on shares of Pfizer from $32.00 to $28.00 and set an “equal weight” rating on the stock in a research note on Friday, December 12th. Guggenheim reiterated a “buy” rating on shares of Pfizer in a report on Wednesday, December 17th. Finally, HSBC restated a “buy” rating and issued a $29.00 price target on shares of Pfizer in a report on Wednesday, December 10th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, thirteen have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $28.00.

Pfizer Trading Up 0.1%

Shares of PFE stock opened at $27.41 on Thursday. The firm has a 50 day moving average price of $25.91 and a two-hundred day moving average price of $25.28. The company has a market capitalization of $155.82 billion, a PE ratio of 20.15 and a beta of 0.47. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $27.94. The company has a quick ratio of 0.97, a current ratio of 1.28 and a debt-to-equity ratio of 0.62.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, topping the consensus estimate of $0.57 by $0.09. The firm had revenue of $17.56 billion for the quarter, compared to analysts’ expectations of $16.93 billion. Pfizer had a return on equity of 20.25% and a net margin of 12.42%.The company’s quarterly revenue was down 1.2% compared to the same quarter last year. During the same quarter last year, the business earned $0.63 EPS. As a group, analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 23rd will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 6.3%. The ex-dividend date is Friday, January 23rd. Pfizer’s dividend payout ratio is currently 126.47%.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.